vancements in artificial heart technology, including next-generation TAHs designed for longer durability and improved hemodynamic performance. While TAHs were initially conceived as temporary support, ongoing research is exploring their potential as a longterm alternative for select patient populations. The integration of bioengineered components and miniaturization of device hardware may revolutionize the field in the coming years.
The Future of Heart Transplantation and MCS
Looking ahead, Dr. Dowling emphasized the role of regenerative medicine and xenotransplantation as potential game-changers in cardiac transplantation. Gene-editing technologies, such as CRISPR, are being investigated to modify pig hearts for human transplantation, potentially addressing the global organ shortage. Early clinical trials in xenotransplantation have yielded promising results, although ethical and immunologic challenges remain. Furthermore, the integration of artificial intelligence( AI) in patient monitoring and decision support is poised to enhance outcomes in both transplantation and MCS. AI-driven predictive analytics may enable earlier identification of complications, personalized treatment adjustments and improved long-term survival.
Additional Notes
To be specific, Dr. Dowling also discussed the progress that was made in the last 50 years on the total artificial heart. The first generation of total artificial heart had four chambers. It was large and it had complications related to thrombosis, infection and size not in proportion to the patient. The new BIVOCORE that was implanted recently at Texas Heart Institute was designed by Dr. Daniel Timms from Australia and implanted at Christ Hospital by Dr. Dowling. This new artificial heart weighs 650g and uses magnetic levitation to pump blood to the body and lungs. There’ s no mechanical wear over time and there is no opportunity for the device to fail, so these are the biggest differences between this technology and the old one.
The FDA approved phase 2 for the trial of this device to be used as a bridge to transplant, and the prediction is that hopefully it will be successful, perhaps on the way to replacing the heart transplant in the future if the technology continues to evolve.
Conclusion
Dr. Dowling’ s insights underscore the dynamic nature of cardiac transplantation and mechanical circulatory support. As technology continues to evolve, the collaborative efforts of surgeons, cardiologists, engineers and researchers will be crucial in pushing the boundaries of innovation. By leveraging advancements in donor organ utilization, MCS and artificial heart technology, the medical community can continue to improve survival and quality of life for patients with end-stage heart failure.
Thank you to Dr. Sam Yared for reviewing this article and adding insights.
* This article was written using AI technology from a transcription of the Senior Physician Committee Meeting and was edited by Dr. Mary Barry.
GLMS FOUNDATION SENIOR PHYSICIANS SPEAKER SERIES
Make sure to add these dates to your calendar so you don’ t miss out! May 6th | June 3rd | August 5th | September 2nd | October 7th | December 2nd
All meetings will take place at noon via Zoom. The program is free and open to GLMS members and their guest. Please contact us for more information on the programs and how to access the meetings.
Senior Physicians Committee Chair, Dr. Sam Yared, has several speakers already lined up, but is always looking for new ideas. If you have suggestions on potential speakers or topics, please reach out, we would love to hear your ideas!
Missed a recent program and want to catch up? Contact us for a link to the recordings. foundation @ glms. org | 502-736-6366
30 LOUISVILLE MEDICINE